Welcome to our dedicated page for Goodrx Holdings news (Ticker: GDRX), a resource for investors and traders seeking the latest updates and insights on Goodrx Holdings stock.
GoodRx Holdings, Inc. (GDRX) operates a leading digital healthcare platform that transforms prescription affordability through price transparency tools and pharmacy benefit solutions. This news hub provides investors and industry professionals with essential updates on financial performance, strategic initiatives, and regulatory developments impacting the company’s role in reshaping medication access.
Discover official press releases covering quarterly earnings, partnership announcements with healthcare stakeholders, and expansions of the company’s prescription savings ecosystem. Our curated collection includes analyses of market trends affecting GoodRx’s position in digital health, updates on telehealth integrations, and coverage of consumer affordability programs.
Key updates include developments in PBM collaborations, Medicare/Medicaid pricing initiatives, and technological advancements within the GoodRx platform. Bookmark this page to monitor how the company navigates evolving healthcare regulations while maintaining its mission to reduce out-of-pocket medication costs for millions of Americans.
GoodRx (Nasdaq: GDRX) has entered a new direct contracting agreement with The Kroger Co. to offer enhanced prescription savings at over 2,200 Kroger pharmacy locations nationwide.
Starting June 1, 2024, patients using a GoodRx coupon can expect almost 50% more savings on most generic medications.
This partnership aims to support Kroger's business objectives and improve patients' access to affordable prescriptions.
GoodRx will discuss this agreement during its Investor Day on May 15 at 9 a.m. ET.
GoodRx Holdings, Inc. reported financial results for the first quarter of 2024. Revenue increased by 8% to $197.9 million, with a net loss of $1.0 million. Adjusted EBITDA was $62.8 million. The company focuses on capital allocation, share repurchases, and M&A. GoodRx anticipates revenue growth for the second quarter and full year 2024.